Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 17, 2014, Pages 6425-6430

  Arias, Juan F ^a,e   Heyer, Lisa N ^a   Von Bredow, Benjamin ^a   Weisgrau, Kim L ^b   Moldt, Brian ^c   Burton, Dennis R ^c,d   Rakasz, Eva G ^b   Evans, David T ^a,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

AIDS; BST 2; CD317; Lentivirus

Indexed keywords

ALPHA INTERFERON; MEMBRANE PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VPU PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL PROTECTION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TARGET CELL; VIRION; VIRUS PARTICLE; WESTERN BLOTTING;

AIDS; BST-2; CD317; LENTIVIRUS;

AMINO ACID SUBSTITUTION; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, CD4; CYTOPROTECTION; GENE DELETION; GPI-LINKED PROTEINS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERFERON-ALPHA; RECEPTORS, CELL SURFACE; RNA INTERFERENCE; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 84899637750     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1321507111     Document Type: Article

References (53)

1. Perez-Caballero D, et al. (2009) Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139(3):499-511.
2. Hammonds J, Wang J-J, Yi H, Spearman P (2010) Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog 6(2):e1000749.
3. Fitzpatrick K, et al. (2010) Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog 6(3):e1000701.
4. Kupzig S, et al. (2003) Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4(10):694-709.
5. VanDamme N, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral vpu protein. Cell Host Microbe 3(4):245-252.
6. Neil SJD, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451(7177):425-430.
7. Mangeat B, et al. (2012) Influenza virus partially counteracts restriction imposed by tetherin/BST-2. J Biol Chem 287(26):22015-22029.
8. Weidner JM, et al. (2010) Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 84(24):12646-12657.
9. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J (2009) Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83(5):2382-2385.
10. Mansouri M, et al. (2009) Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 83(19):9672-9681.
11. Jouvenet N, et al. (2009) Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83(4):1837-1844.
12. Sauter D, et al. (2009) Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6(5):409-421.
13. Zhang F, et al. (2009) Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6(1):54-67.
14. Jia B, et al. (2009) Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5(5):e1000429.
15. LeTortorec A, Neil SJD (2009) Antagonism and intracellular sequestration of human tetherin by the HIV-2 envelope glycoprotein. J Virol 83(22):11966-11978.
16. Liberatore RA, Bieniasz PD (2011) Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci USA 108(44): 18097-18101.
17. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT (2011) Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nefdeleted SIV. Cell Host Microbe 9(1):46-57.
18. Götz N, et al. (2012) Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe 12(3): 373-380.
19. Jolly C, Booth NJ, Neil SJ (2010) Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 84(23):12185-12199.
20. Gummuluru S, Kinsey CM, Emerman M (2000) An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol 74(23):10882-10891.
21. Alpert MD, et al. (2012) A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1-or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J Virol 86(22):12039-12052.
22. Schubert U, et al. (1998) CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol 72(3):2280-2288.
23. Shah AH, et al. (2010) Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 8(5):397-409.
24. Iwabu Y, et al. (2009) HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 284(50):35060-35072.
25. Mangeat B, et al. (2009) HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 5(9): e1000574.
26. Skasko M, et al. (2012) HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J Biol Chem 287(1):58-67.
27. McNatt MW, Zang T, Bieniasz PD (2013) Vpu binds directly to tetherin and displaces it from nascent virions. PLoS Pathog 9(4):e1003299.
28. Vigan R, Neil SJ (2010) Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol 84(24): 12958-12970.
29. Skasko M, et al. (2011) BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology 411(1): 65-77.
30. Mitchell RS, et al. (2009) Vpu antagonizes BST-2-mediated restriction of HIV-1 release via β-TrCP and endo-lysosomal trafficking. PLoS Pathog 5(5):e1000450.
31. Douglas JL, et al. (2009) Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a βTrCP-dependent mechanism. J Virol 83(16):7931-7947.
32. Tokarev AA, Munguia J, Guatelli JC (2011) Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol 85(1):51-63.
33. Gustin JK, Douglas JL, Bai Y, Moses AV (2012) Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain. J Biol Chem 287(18):14837-14850.
34. Margottin F, et al. (1996) Interaction between the cytoplasmic domains of HIV-1 Vpu and CD4: role of Vpu residues involved in CD4 interaction and in vitro CD4 degradation. Virology 223(2):381-386.
35. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC (2010) BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 18(9): 388-396.
36. Neil SJD, Sandrin V, Sundquist WI, Bieniasz PD (2007) An interferon-α-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2(3):193-203.
37. Cocka LJ, Bates P (2012) Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog 8(9):e1002931.
38. Galão RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ (2012) Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe 12(5):633-644.
39. Tokarev A, et al. (2013) Stimulation of NF-κB activity by the HIV restriction factor BST2. J Virol 87(4):2046-2057.
40. Hessell AJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158):101-104.
41. Alpert MD, et al. (2012) ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8(8):e1002890.
42. Haynes BF, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366(14):1275-1286.
43. Chung AW, et al. (2011) Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 108(18):7505-7510.
44. Carlson JM, Brumme ZL (2008) HIV evolution in response to HLA-restricted CTL selection pressures: A population-based perspective. Microbes Infect 10(5):455-461.
45. Yagita M, et al. (2000) A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14(5): 922-930.
46. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP (1999) A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 73(11):8966-8974.
47. Adachi A, et al. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59(2):284-291.
48. Koyanagi Y, et al. (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236(4803):819-822.
49. Wong SK, et al. (2009) A New World primate deficient in tetherin-mediated restriction of human immunodeficiency virus type 1. J Virol 83(17):8771-8780
50. Gibbs JS, Regier DA, Desrosiers RC (1994) Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res Hum Retroviruses 10(4): 343-350.
51. Maldarelli F, Chen MY, Willey RL, Strebel K (1993) Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol 67(8): 5056-5061.
52. Vujcic LK, Quinnan GV, Jr. (1995) Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res Hum Retroviruses 11(7):783-787.
53. Carter CC, et al. (2010) HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16(4):446-451.